Sygnature Discovery has announced two key appointments: Dr Allan Jordan as as director of oncology drug discovery, and Ms Louisa Jordison in the newly-created position of director of strategic planning.
In Allan’s new role his primary focus will be to augment Sygnature’s existing oncology drug discovery capabilities and cellular biology. Allan joins Sygnature from Cancer Research UK where he worked for the past decade. A very well-known and respected figure in the global oncology research sector, his appointment plays a key part in Sygnature’s strengthening of their expertise in their key therapeutic areas, which in addition to oncology are neuroscience and immunology.
Louisa will play a key role in the company’s ambitious planning, growth and capital projects activities. She brings a wealth of experience in senior level corporate finance from companies including Experian, Deloitte and KPMG.
Sygnature Discovery’s CEO, Dr Simon Hirst commented: “Louisa’s and Allan’s appointments mark a further step in the development of Sygnature as a leading player in the global drug discovery and pre-clinical CRO sector. They demonstrate our commitment to sustainable and secure growth of our company and continuing to broaden and enrich our in-house capabilities and therapeutic area expertise so that we are in an optimal position to serve our growing customer base”.
